Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of BioCentury Extra, The Daily News: Financial News

BioCentury Extra, The Daily News Current Issue
  • FINANCIAL NEWS: Acadia raises $100 million in follow-on

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) raised $100 million through the sale of 8 million shares at $12.50 in a follow-on underwritten by Jefferies; Cowen; JMP Securities; Needham; Ladenburg Thalmann; Roth Capital …

    Published on 5/15/2013
  • FINANCIAL NEWS: Ambit bumps shares, lowers price for proposed IPO

    Ambit Biosciences Corp. (San Diego, Calif.) amended its IPO and now plans to sell more shares at a lower price. The company plans to sell 8.1 million shares at $8, which would raise $65 million and value the company at…

    Published on 5/15/2013
  • FINANCIAL NEWS: bluebird bio files for IPO

    Gene therapy company bluebird bio Inc. (Cambridge, Mass.) filed to raise up to $86.3 million in an IPO underwritten by JPMorgan; BofA Merrill Lynch; Cowen; Canaccord; and Wedbush. Late this year, the biotech plans to …

    Published on 5/15/2013
  • FINANCIAL NEWS: Kite raises $20 million in series A

    Cancer immunotherapy company Kite Pharma Inc. (Los Angeles, Calif.) raised $20 million in a series A round. The company also converted $15 million in outstanding promissory notes from Kite's seed round into series A …

    Published on 5/15/2013
  • FINANCIAL NEWS: Rockwell Medical raises $35 million

    Rockwell Medical Technologies Inc. (NASDAQ:RMTI) raised $35 million through the sale of 11.5 million shares at $3.05 in a follow-on underwritten by Chardan Capital Markets; Summer Street; and C&Co/Prince Ridge. Rockwell…

    Published on 5/15/2013
  • FINANCIAL NEWS: Tokai raises $35.5 million in E round

    Tokai Pharmaceuticals Inc. (Cambridge, Mass.) raised $35.5 million in a series E round from existing investors Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors. Tokai's galeterone …

    Published on 5/15/2013
  • FINANCIAL NEWS: Vivus planning $200 million note offering

    Vivus Inc. (NASDAQ:VVUS) said it plans to raise $200 million through the sale of unsecured senior convertible notes due May 1, 2020. The company markets obesity drug Qsymia phentermine/topiramate in the U.S. Last week, …

    Published on 5/15/2013
  • FINANCIAL NEWS: Acadia planning follow-on

    Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) proposed a follow-on late Tuesday underwritten by Jefferies; Cowen; JMP Securities; and Needham. Acadia plans to submit an NDA to FDA for pimavanserin around the end of next …

    Published on 5/14/2013
  • FINANCIAL NEWS: Callidus raises $4.6M in series A

    Callidus Biopharma Inc. (Doylestown, Pa.) debuted on Tuesday with $4.6 million in a series A round led by two undisclosed investors, with participation from undisclosed private investors. Callidus is attaching insulin-…

    Published on 5/14/2013
  • FINANCIAL NEWS: Esperion files for IPO

    Esperion Therapeutics Inc. (Plymouth, Mich.) filed to raise up to $70 million in an IPO underwritten by Credit Suisse; Citigroup; JMP Securities; and Nicolaus Weisel. Esperion's ETC-1002 is in two Phase IIa trials to …

    Published on 5/14/2013
  • FINANCIAL NEWS: Third Rock names new venture partners

    Healthcare VC firm Third Rock Ventures named John Maraganore, CEO of RNAi company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), a venture partner. Third Rock also named Daniel Lynch and Steven Paul as venture partners. …

    Published on 5/14/2013
  • FINANCIAL NEWS: Dyax planning $30 million offering

    Dyax Corp. (NASDAQ:DYAX) proposed to raise about $30 million through the sale of 8.9 million common shares at $2.30 and 41,418 shares of series 1 convertible preferred shares at $230 in a registered direct offering to …

    Published on 5/13/2013
  • FINANCIAL NEWS: Optimer gains on further take out rumors

    Shares of Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) jumped $1.85 (14%) to $14.66 on Monday after media reports surfaced that at least three companies made bids to acquire the company. The companies rumored to have made…

    Published on 5/13/2013
  • FINANCIAL NEWS: Discovery Labs raises $14.3 million in follow-on

    Discovery Laboratories Inc. (NASDAQ:DSCO) raised $14.3 million on Friday through the sale of 9.5 million shares at $1.50 in a follow-on underwritten by Stifel Nicolaus Weisel. Discovery Labs proposed the offering late …

    Published on 5/10/2013
  • FINANCIAL NEWS: Optimer falls on 1Q13 financial results

    Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) fell $2.11 (14%) to $12.81 on Friday after reporting 1Q13 financial results late Thursday that missed the Street. The company reported a 1Q13 loss per share of $0.65, wider …

    Published on 5/10/2013
  • FINANCIAL NEWS: Sequenom jumps on 1Q13 revenues

    Sequenom Inc. (NASDAQ:SGNM) gained $0.47 (13%) to $4.04 on Friday after the company reported 1Q13 revenues of $38.5 million, up 158% over $14.9 million in 1Q12. The Street was expecting $38.3 million. Diagnostics …

    Published on 5/10/2013
  • FINANCIAL NEWS: Warburg Pincus raises $11.2B for eleventh fund

    Warburg Pincus raised $11.2 billion for its eleventh fund, Warburg Pincus Private Equity XI. Warburg invests in healthcare, energy, financial services, technology, media and telecommunications and consumer, industrial …

    Published on 5/10/2013
  • FINANCIAL NEWS: AnGes looks to raise at least $51.2M

    Japanese gene therapy company AnGes MG Inc. (Tokyo:4563) said it hopes to raise at least Y5.1 billion ($51.2 million) through May 19, 2014, through the exercise of 20,000 stock acquisition rights by Merrill Lynch Japan …

    Published on 5/9/2013
  • FINANCIAL NEWS: Dendreon slides on Provenge sales miss

    Shares of Dendreon Corp. (NASDAQ:DNDN) slid $0.71 (15%) to $4.03 on Thursday after the company reported 1Q13 net revenues of prostate cancer drug Provenge sipuleucel-T -- the company's sole marketed product -- that …

    Published on 5/9/2013
  • FINANCIAL NEWS: Frazier raises $282M of $300M for seventh fund

    Frazier Healthcare raised $281.8 million of a planned $300 million for its seventh fund, Frazier Healthcare VII, according to an SEC filing. Frazier's prior fund closed at $600 million in 2007. The firm is primarily …

    Published on 5/9/2013
  • FINANCIAL NEWS: Isis raises $171 million in follow-on

    Antisense technology company Isis Pharmaceuticals Inc. (NASDAQ:ISIS) raised $171 million through the sale of 9 million shares at $19 million in a follow-on underwritten by Goldman Sachs; JPMorgan; Stifel Nicolaus Weisel…

    Published on 5/9/2013
  • FINANCIAL NEWS: NPS reports first Gattex sales

    NPS Pharmaceuticals Inc. (NASDAQ:NPSP) reported 1Q13 earnings on Thursday, including $654,000 in the first sales of Gattex teduglutide, which the company launched in the U.S. in February to treat short bowel syndrome (…

    Published on 5/9/2013
  • FINANCIAL NEWS: Omeros planning $16.2 million offering

    Omeros Corp. (NASDAQ:OMER) proposed late Thursday to raise $16.2 million through the sale of 3.9 million shares at $4.14 in a registered direct offering to RA Capital Management and undisclosed investors. The price is a…

    Published on 5/9/2013
  • FINANCIAL NEWS: Receptos raises $72.8 million in IPO

    Receptos Inc. (NASDAQ:RCPT) raised $72.8 million through the sale of 5.2 million shares at $14 in an IPO late Wednesday. Credit Suisse; Leerink; BMO Capital Markets; and Wedbush are underwriters. The price -- at the low…

    Published on 5/9/2013
  • FINANCIAL NEWS: Jazz reports 1Q13 results, slides on Xyrem generic competition concerns

    Jazz Pharmaceuticals plc (NASDAQ:JAZZ) disclosed in a 10-Q late Tuesday that a modified REMS for narcolepsy drug Xyrem sodium oxybate could include new requirements that could "make it easier for future generic …

    Published on 5/8/2013

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or never received a password, please click above to receive a new one.

The Daily Extra

Concise and authoritative news for biotech and pharma, written each business day by BioCentury’s senior editors and analysts.


Find out how to get your biopharma daily news update.